Phase II Randomized Pilot Comparing HDR and LDR Monotherapy for Intermediate Risk Prostate Cancer: Report of Dose Escalation to Dominant Intraprostatic Lesions

Tisseverasinghe, Steven; Crook, Juanita; Farnquist, Brenda; Araujo, Cynthia; Batchelar, Deidre; Hilts, Michelle; Bachand, François

doi:10.1016/j.brachy.2018.04.021

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many studies have proved that in current radiation therapy, 125 I seed-based low-dose-rate (LDR) radiotherapy presents better efficacy and safety than high-dose-rate (HDR) radiotherapy [ 18 ] In addition, stereotactic radiotherapy for body tumors (SBRT) has more and more clinical applications due to its good efficacy and low side effects. SBRT is based on the characteristics, location, and size of the tumor, using different radiotherapy segmentation modes [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

Endovascular implantation of iodine-125 seed strand combined and stent placement for locally advanced pancreatic ductal adenocarcinoma with vascular invasion: a prospective single-arm pilot study

Wu¹,

Zhang²,

Zhang³

et al. 2020

jcb

View full text Add to dashboard Cite

Purpose To investigate the safety and feasibility of endovascular brachytherapy using iodine-125 ( 125 I) seed strand for locally advanced pancreatic ductal adenocarcinoma (PDAC) with vascular invasion. Material and methods From January 2010 to January 2015, 12 patients diagnosed with locally advanced, inoperable PDAC with splenic or superior mesenteric vein invasion were enrolled in the present study and received endovascular brachytherapy combined with regional intra-arterial infusion chemotherapy. Standardized software was used for dose calculation. Procedure-related and radiation complications were documented and assessed. Overall survival was calculated with the Kaplan-Meier approach. Results The technical success rate of 125 I seed strand implantation and stent placement was 100%. During follow-up with a mean duration of 17.00 ±6.07 months (range, 6~24 months), the mean and median survival times were 12.0 ±2.4 months (95% CI: 7.4~16.6 months) and 10.7 ±1.4 months (95% CI: 8.0~13.5 months), respectively. One month after the treatment, the disease control and objective rates were 83.8% and 58.3%, respectively. The 6-, 12-, and 15-month cumulative survival rates were 66.7%, 47.6%, and 9.5%, respectively. Conclusions Endovascular brachytherapy using 125 I seed strand and stent placement may be a safe and effective treatment option for locally advanced pancreatic duct adenocarcinoma with vascular invasion.

show abstract

Section: Discussionmentioning

confidence: 99%